These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 39131157)

  • 1. 4th booster-dose SARS-CoV-2 heterologous and homologous vaccination in rheumatological patients.
    Gallardo-Nelson MJ; Cruces M; Gómez YM; Fuenzalida C; Silva J; Aravena-Traipi L; Nuñez E; Gaete-Angel A; Rivas-Yañez E; Kalergis AM; Soto-Rifo R; Valiente-Echeverria F
    Front Immunol; 2024; 15():1427501. PubMed ID: 39131157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune response against the SARS-CoV-2 spike protein in cancer patients after COVID-19 vaccination during the Omicron wave: a prospective study.
    Muñoz-Gómez MJ; Ryan P; Quero-Delgado M; Martin-Vicente M; Cuevas G; Valencia J; Jiménez E; Blanca-López N; Lara-Álvarez MÁ; Hernández-Rivas JÁ; Redondo G; Mas V; Sepúlveda-Crespo D; Vázquez M; Torres-Macho J; Martínez I; Resino S
    J Infect Public Health; 2024 Jul; 17(7):102473. PubMed ID: 38865774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost.
    Ai J; Zhang H; Zhang Y; Lin K; Zhang Y; Wu J; Wan Y; Huang Y; Song J; Fu Z; Wang H; Guo J; Jiang N; Fan M; Zhou Y; Zhao Y; Zhang Q; Liu Q; Lv J; Li P; Qiu C; Zhang W
    Emerg Microbes Infect; 2022 Dec; 11(1):337-343. PubMed ID: 34935594
    [No Abstract]   [Full Text] [Related]  

  • 4. Specific Cellular and Humoral Response after the Third Dose of Anti-SARS-CoV-2 RNA Vaccine in Patients with Immune-Mediated Rheumatic Diseases on Immunosuppressive Therapy.
    Mohamed Mohamed K; Álvarez-Hernández MP; Jiménez García C; Guevara-Hoyer K; Freites D; Martínez Prada C; Pérez-Sancristóbal I; Fernández Gutiérrez B; Mato Chaín G; Rodero M; Rodríguez de la Peña A; Mulero T; Bravo C; Toledano E; Culebras López E; Mediero Valeros B; Pérez Segura P; Sánchez-Ramón S; Candelas Rodríguez G
    Biomedicines; 2023 Aug; 11(9):. PubMed ID: 37760858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repeated Omicron infection dampens immune imprinting from previous vaccination and induces broad neutralizing antibodies against Omicron sub-variants.
    Gong X; Peng L; Wang F; Liu J; Tang Y; Peng Y; Niu S; Yin J; Guo L; Lu H; Liu Y; Yang Y
    J Infect; 2024 Aug; 89(2):106208. PubMed ID: 38908522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutralizing antibody responses and cellular responses against SARS-CoV-2 Omicron subvariants after mRNA SARS-CoV-2 vaccination in kidney transplant recipients.
    Kawashiro K; Suzuki R; Nogimori T; Tsujino S; Iwahara N; Hirose T; Okada K; Yamamoto T; Fukuhara T; Hotta K; Shinohara N
    Sci Rep; 2024 May; 14(1):12176. PubMed ID: 38806644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity of COVID-19 booster vaccination in IEI patients and their one year clinical follow-up after start of the COVID-19 vaccination program.
    van Leeuwen LPM; Grobben M; GeurtsvanKessel CH; Ellerbroek PM; de Bree GJ; Potjewijd J; Rutgers A; Jolink H; van de Veerdonk FL; van Gils MJ; de Vries RD; Dalm VASH;
    Front Immunol; 2024; 15():1390022. PubMed ID: 38698851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies.
    Wang X; Zhao X; Song J; Wu J; Zhu Y; Li M; Cui Y; Chen Y; Yang L; Liu J; Zhu H; Jiang S; Wang P
    Emerg Microbes Infect; 2022 Dec; 11(1):477-481. PubMed ID: 35034583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of COReNAPCIN, a SARS-CoV-2 mRNA vaccine, as a fourth heterologous booster in healthy Iranian adults: A double-blind, randomized, placebo-controlled, phase 1 clinical trial with a six-month follow-up.
    Salehi M; Alavi Darazam I; Nematollahi A; Alimohammadi M; Pouya S; Alimohammadi R; Khajavirad N; Porgoo M; Sedghi M; Mahdi Sepahi M; Azimi M; Hosseini H; Mahmoud Hashemi S; Dehghanizadeh S; Khoddami V
    Int Immunopharmacol; 2024 Jun; 134():112192. PubMed ID: 38761778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
    Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
    Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterologous Ad26.COV2.S booster after primary BBIBP-CorV vaccination against SARS-CoV-2 infection: 1-year follow-up of a phase 1/2 open-label trial.
    Muangnoicharoen S; Wiangcharoen R; Lawpoolsri S; Nanthapisal S; Jongkaewwattana A; Duangdee C; Kamolratanakul S; Luvira V; Thanthamnu N; Chantratita N; Thitithanyanont A; Anh Wartel T; Excler JL; Ryser MF; Leong C; Mak TK; Pitisuttithum P
    Vaccine; 2024 Jul; 42(19):3999-4010. PubMed ID: 38744598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial.
    Bennett C; Woo W; Bloch M; Cheung K; Griffin P; Mohan R; Deshmukh S; Arya M; Cumming O; Neville AM; McCallum Pardey TG; Plested JS; Cloney-Clark S; Zhu M; Kalkeri R; Patel N; Marcheschi A; Swan J; Smith G; Cho I; Glenn GM; Walker R; Mallory RM;
    Lancet Infect Dis; 2024 Jun; 24(6):581-593. PubMed ID: 38460525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera.
    Muik A; Lui BG; Wallisch AK; Bacher M; Mühl J; Reinholz J; Ozhelvaci O; Beckmann N; Güimil Garcia RC; Poran A; Shpyro S; Finlayson A; Cai H; Yang Q; Swanson KA; Türeci Ö; Şahin U
    Science; 2022 Feb; 375(6581):678-680. PubMed ID: 35040667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interchangeability of different COVID-19 vaccine platforms as booster doses: A phase 3 study mimicking real-world practice.
    Ann Costa Clemens S; Weckx L; Milan EP; Smolenov I; Clemens R
    Vaccine; 2024 Jul; 42(19):3989-3998. PubMed ID: 38762360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do immunosuppressive treatments influence immune responses against adenovirus-based COVID-19 vaccines in patients with multiple sclerosis? An Argentine multicenter study.
    Silva BA; Miglietta E; Casabona JC; Wenker S; Eizaguirre MB; Alonso R; Casas M; Lázaro LG; Man F; Portuondo G; Lopez Bisso A; Zavala N; Casales F; Imhoff G; Steinberg DJ; López PA; Carnero Contentti E; Deri N; Sinay V; Hryb J; Chiganer E; Leguizamon F; Tkachuk V; Bauer J; Ferrandina F; Giachello S; Henestroza P; Garcea O; Pascuale CA; Heitrich M; Podhajcer OL; Vinzón S; D'Alotto-Moreno T; Benatar A; Rabinovich GA; Pitossi FJ; Ferrari CC
    Front Immunol; 2024; 15():1431403. PubMed ID: 39224589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Follow-Up and Comparative Assessment of SARS-CoV-2 IgA, IgG, Neutralizing, and Total Antibody Responses After BNT162b2 or mRNA-1273 Heterologous Booster Vaccination.
    Younes S; Nicolai E; Pieri M; Bernardini S; Daas HI; Al-Sadeq DW; Younes N; Shurrab FM; Nizamuddin PB; Humaira F; Al-Dewik N; Yassine HM; Abu-Raddad LJ; Ismail A; Nasrallah GK
    Influenza Other Respir Viruses; 2024 May; 18(5):e13290. PubMed ID: 38706402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and Safety of Heterologous Omicron BA.1 and Bivalent SARS-CoV-2 Recombinant Spike Protein Booster Vaccines: A Phase 3 Randomized Clinical Trial.
    Bennett C; Rivers EJ; Woo W; Bloch M; Cheung K; Griffin P; Mohan R; Deshmukh S; Arya M; Cumming O; Neville AM; Pardey TM; Plested JS; Cloney-Clark S; Zhu M; Kalkeri R; Patel N; Buchanan A; Marcheschi A; Swan J; Smith G; Cho I; Glenn GM; Walker R; Mallory RM
    J Infect Dis; 2024 Jul; 230(1):e4-e16. PubMed ID: 39052718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of COVID-19 mRNA vaccine symptomatic breakthrough infections during Omicron circulation in adults with or without infection prior to vaccination.
    Durier C; Ninove L; van der Werf S; Lefebvre M; Desaint C; Bauer R; Attia M; Lecompte AS; Lachatre M; Maakaroun-Vermesse Z; Nicolas JF; Verdon R; Kiladjian JJ; Loubet P; Schmidt-Mutter C; Corbin V; Ansart S; Melica G; Resch M; Netzer E; Kherabi Y; Tardieu R; Lelièvre JD; Tartour E; Meyer L; de Lamballerie X; Launay O;
    Infect Dis Now; 2024 Aug; 54(5):104886. PubMed ID: 38494117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune responses to mRNA vaccines against SARS-CoV-2 in patients with immune-mediated inflammatory rheumatic diseases.
    Sieiro Santos C; Calleja Antolin S; Moriano Morales C; Garcia Herrero J; Diez Alvarez E; Ramos Ortega F; Ruiz de Morales JG
    RMD Open; 2022 Jan; 8(1):. PubMed ID: 34987093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.